Skip to main content

Table 1 Clinicopathological characteristics before and after PSM

From: Impact of surgical margin width on long-term outcomes for intrahepatic cholangiocarcinoma: a multicenter study

  Before PSM After PSM
Wide Narrow P-Value Wide Narrow P-Value
(n = 195) (n = 283) (n = 79) (n = 79)
Gender
 Male 103 (52.8%) 184 (65.0%) 0.010 51 (64.6%) 47 (59.5%) 0.623
 Female 92 (47.2%) 99 (35.0%)   28 (35.4%) 32 (40.5%)  
Age
  ≤ 60 years 115(59.0%) 177(62.5%) 0.489 42(53.2%) 50(63.3%) 0.259
  > 60 years 80(41.0%) 106(7.5%)   37(46.8%) 29(36.7%)  
HBsAg
 Negative 144 (73.8%) 184 (65.0%) 0.052 55(69.6%) 59(74.7%) 0.594
 Positive 51 (26.2%) 99 (35.0%)   24(30.4%) 20(25.3%)  
CA19–9
  ≤ 200 U/mL 136 (69.7%) 253 (89.4%) < 0.001 63(79.7%) 65(82.3%) 0.839
  > 200 U/mL 59 (30.3%) 30 (10.6%)   16(20.3%) 14(17.7%)  
CEA
  ≤ 5 μg/L 125 (64.1%) 234 (82.7%) < 0.001 56(70.9%) 56(70.9%) 1.000
  > 5 μg/L 70 (35.9%) 49 (17.3%)   23(29.1%) 23(29.1%)  
Blood loss
  ≤ 400 mL 141(72.3%) 229(80.9%) 0.036 61(77.2%) 57(72.2%) 0.583
 >400 mL 54(27.7%) 54(19.1%)   18(22.8%) 22(27.8%)  
Transfusion
 No 148(75.9%) 246(86.9%) 0.003 60(75.9%) 61(77.2%) 1.000
 Yes 47(24.1%) 37(13.1%)   19(24.1%) 18(22.8%)  
Laparoscopic approach
 No 163 (83.6%) 281 (99.3%) < 0.001 76 (96.2%) 77 (97.5%) 1.000
 Yes 32 (16.4%) 2 (0.7%)   3 (3.8%) 2 (2.5%)  
Major hepatectomy
 No 72 (36.9%) 80 (28.3%) 0.058 32(40.5%) 31(39.2%) 1.000
 Yes 123 (63.1%) 203(71.7%)   47(59.5%) 48(60.8%)  
Complications
 No 137 (70.3%) 233 (82.3%) 0.003 60 (75.9%) 59 (74.7%) 1.000
 Yes 58 (29.7%) 50 (17.7%)   19 (24.1%) 20 (25.3%)  
Tumor size
  ≤ 5 cm 86 (44.1%) 94 (33.2%) 0.020 37(46.8%) 34(43.0%) 0.749
  > 5 cm 109 (55.9%) 189 (66.8%)   42(53.2%) 45(57.0%)  
Tumor number
 Single 163 (83.6%) 181 (64.0%) < 0.001 61(77.2%) 60(75.9%) 1.000
 Multiple 32 (16.4%) 102 (36.0%)   18(22.8%) 19(24.1%)  
Lymph node invasion
 No 140 (71.8%) 250 (88.3%) < 0.001 67 (84.8%) 69 (87.3%) 0.818
 Yes 55 (28.2%) 33 (11.7%)   12 (15.2%) 10 (12.7%)  
Mass-forming
 No 38 (19.5%) 116 (41.0%) < 0.001 28(35.4%) 19(24.1%) 0.164
 Yes 157 (80.5%) 167 (59.0%)   51(64.6%) 60(75.9%)  
Tumor differentiation
 Well &Moderate 139 (71.3%) 236 (83.4%) 0.002 64(81.0%) 60(75.9%) 0.561
 Poor 56 (28.7%) 47 (16.6%)   15(19.0%) 19(24.1%)  
Satellite
 No 170 (87.2%) 181 (64.0%) < 0.001 65(82.3%) 62(78.5%) 0.689
 Yes 25 (12.8%) 102 (36.0%)   14(17.7%) 17(21.5%)  
MVI
 No 165 (84.6%) 254 (89.8%) 0.124 72(91.1%) 68(86.1%) 0.453
 Yes 30 (15.4%) 29 (10.2%)   7(8.9%) 11(13.9%)  
Perineural invasion
 No 164 (84.1%) 261 (92.2%) 0.008 66(83.5%) 69(87.3%) 0.652
 Yes 31 (15.9%) 22 (7.8%)   13(16.5%) 10(12.7%)  
p-AT
 No 141(72.3%) 240(84.8%) 0.001 64(81.0%) 66(83.5%) 0.835
 Yes 54(27.7%) 43(15.2%)   15(19.0%) 13(16.5%)  
  1. Abbreviations: PSM propensity score matching, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, HBsAg hepatitis B surface antigen, MVI microvascular invasion, p-AT postoperative adjuvant therapy